Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;15(4):891-900.
doi: 10.1007/s13193-024-01976-0. Epub 2024 Jul 4.

Combined Fluorescein and Methylene Blue Dye for Sentinel Lymph Node Biopsy in Patients of Early Carcinoma Breast: A Promising Technique

Affiliations

Combined Fluorescein and Methylene Blue Dye for Sentinel Lymph Node Biopsy in Patients of Early Carcinoma Breast: A Promising Technique

Rajandeep Singh Sethi et al. Indian J Surg Oncol. 2024 Dec.

Abstract

Sentinel lymph node biopsy is currently the gold standard for clinically node-negative patients of carcinoma breast. Fluorescein is a safe, low-cost agent, and easily available. Fluorescein has shown a promising role in sentinel lymph node evaluation in carcinoma breast in combination with methylene blue dye with a detection rate of more than 90% and a false-negative rate of less than 10% in previous studies. This study aims to determine the detection rate and diagnostic accuracy of fluorescein and methylene blue dye in early breast cancer. The identification rate and false-negative rate of the combined blue and fluorescent dye method were 100% and 7.14% respectively. The accuracy of the combined blue and fluorescein dye method was 98.3%. The sensitivity, specificity, negative predictive value, and positive predictive value of the combined blue dye and fluorescein dye method were 92.8%, 100%, 97.8%, and 100% respectively. Thus, the combined blue and fluorescein dye method is an easy, safe, cost-effective, and reliable method of sentinel lymph node biopsy in early breast cancer patients.

Keywords: Axillary lymph node dissection; Early breast carcinoma; Fluorescein; Methylene blue dye; Sentinel lymph node biopsy.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe authors declare no competing interests.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249 - PubMed
    1. Nandakumar A, Anantha N, Venugopal TC, Sankaranarayanan R, Thimmasetty K, Dhar M (1995) Survival in breast cancer: a populationbased study in Bangalore. India Int J Cancer 60:593–596 - PubMed
    1. Coleman MP et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9(8):730–756 - PubMed
    1. Bélanger J, Soucy G, Sidéris L, Leblanc G, Drolet P, Mitchell A, et al (2008) Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count. J Am Coll Surg 206(4):704–708. 10.1016/j.jamcollsurg.2007.10.016 - PubMed
    1. Minami S, Sakimura C, Irie J, Tokai Y, Okubo H, Ohno T (2021) Predictive factors among clinicopathological characteristics for sentinel lymph node metastasis in T1–T2 breast cancer. Cancer Manag Res 13:215–223 - PMC - PubMed